RNS Number : 4804W
N4 Pharma PLC
18 April 2023

18 April 2023

N4 Pharma Plc
("**N4 Pharma**" or the "**Company**")

siRNA update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on its ongoing siRNA research work.

The Company has completed the single loading of both the EGFR and BCL-2 siRNA nucleotides onto Nuvec and has produced good monodisperse formulations at all doses to be investigated. The single loaded EGFR siRNA has shown strong silencing of the EGFR gene with a good dose response curve established which has allowed the Company to identify the dose it can take into the single loaded EGFR *in vivo* study.

The next step for EGFR is to measure cell apoptosis to show a relevant *in vitro* clinical effect.

Supply of siRNA is only available from a few sources and supply issues means the Company is still establishing the BCL-2 assay to be used for the *in vitro* testing. An initial effect has been seen but to complete the dose response curve more material is needed to fully establish the assay and determine the doses to move into the single loaded *in vivo* work and double loaded experiments.

The Company has also established the growth curve of the xenograft tumour model to be used, so once the BCL-2 *in vitro* work is complete, the Company will be ready to start the *in vivo* studies, as long as supply of the siRNA is not further interrupted.

Nigel Theobald, Chief Executive Officer of the Company, commented:

"We are very pleased with the EGFR results which show excellent knockdown of the siRNA along with a very clear dose response curve and believe this shows how well suited Nuvec® is for working with siRNA."

Enquiries:

N4 Pharma Plc — Via IFC Advisory

Nigel Theobald, CEO

Luke Cairns, Executive Director

SP Angel Corporate Finance LLP — Tel: +44 (0)20 3470 0470

Nominated Adviser and Joint Broker

Matthew Johnson/Kasia Brzozowska (Corporate Finance)

Vadim Alexandre/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited — Tel: +44 (0)20 3657 0050

Joint Broker

Andy Thacker

IFC Advisory Limited — Tel: +44 (0)20 3934 6630

Financial PR

Graham Herring

Zach Cohen

Glossary

siRNA: silencing RNA / short interfering RNA

Nucleotides: organic molecules composed of a nitrogenous base, a pentose sugar and a phosphate.

EGFR: epidermal growth factor receptor, is found on the surface of some normal cells and is involved in cell growth. It may also be found at high levels on some types of cancer cells, which causes these cells to grow and divide.

Bcl-2: (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins that regulate cell death.

Monodisperse: (of a colloid) containing particles of uniform size.

Xenograft tumour model: in vivo model where human tumour cells are grown to form a tumour.

Cell apoptosis: the process of programmed cell death.

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RESBUGDSSDBDGXR